Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Goes Public, Stock Soars 200 Percent

Premium

S

AN DIEGO--Sequenom made an initial public offering earlier this month of 6 million shares of stock at $26 per share, which yielded gross proceeds of about $157 million. The shares gained more than 200 percent and closed day one at nearly $80.

The company, which calls itself an industrial genomics firm addressing the large-scale commercial use of DNA variations for improving health, agriculture, and livestock, said its intellectual property portfolio includes 47 pending patent applications in the US. Sequenom’s MassArray system performs high-throughput analysis of SNPs. The technology is presently being tested at six academic, government, and commercial sites.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.